source
- Novo says launch of obesity drug CagriSema in Europe delayed by a couple of yearsNovo Nordisk announced it will not bring its obesity candidate CagriSema to European markets for the next few years. The statement came from the company's outgoing chief financial officer, Karsten…
- Kamau Therapeutics presents first clinical data from its updated sickle-cell gene-editing programKamau Therapeutics, a biotech company that entered the scene in 2023, has released clinical data from its reengineered sickle‑cell gene‑editing program for the first time. The disclosure marks the…